Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

About this update from Dianthus Therapeutics, Inc.

NEW YORK and WALTHAM, Mass. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia , Chief Executive Officer, at the following healthcare investor conferences during November and December 2024 : Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MA Jefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London 7th Annual Evercore HealthCONx Conference on December 4 at 10:50 a.m. ET in Coral Gables, FL Live webcasts of the Company’s presentations at these three conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website . About Dianthus Therapeutics Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass. , Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn . Contact Jennifer Davis Ruff Dianthus Therapeutics [email protected] Source: Dianthus Therapeutics, Inc.

View stock analysis, news, and events for Dianthus Therapeutics, Inc.